These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 26640141)

  • 1. PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling.
    Cheng H; Liu P; Ohlson C; Xu E; Symonds L; Isabella A; Muller WJ; Lin NU; Krop IE; Roberts TM; Winer EP; Arteaga CL; Zhao JJ
    Oncogene; 2016 Jun; 35(23):2961-70. PubMed ID: 26640141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibitors of STAT3, β-catenin, and IGF-1R sensitize mouse PIK3CA-mutant breast cancer to PI3K inhibitors.
    Merino VF; Cho S; Liang X; Park S; Jin K; Chen Q; Pan D; Zahnow CA; Rein AR; Sukumar S
    Mol Oncol; 2017 May; 11(5):552-566. PubMed ID: 28296140
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transcriptome- and proteome-oriented identification of dysregulated eIF4G, STAT3, and Hippo pathways altered by PIK3CA
    Cheng F; Zhao J; Hanker AB; Brewer MR; Arteaga CL; Zhao Z
    Breast Cancer Res Treat; 2016 Dec; 160(3):457-474. PubMed ID: 27771839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
    Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis.
    Hu L; Liang S; Chen H; Lv T; Wu J; Chen D; Wu M; Sun S; Zhang H; You H; Ji H; Zhang Y; Bergholz J; Xiao ZJ
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E3964-E3973. PubMed ID: 28468801
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers.
    Bonazzoli E; Cocco E; Lopez S; Bellone S; Zammataro L; Bianchi A; Manzano A; Yadav G; Manara P; Perrone E; Haines K; Espinal M; Dugan K; Menderes G; Altwerger G; Han C; Zeybek B; Litkouhi B; Ratner E; Silasi DA; Huang GS; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2019 Apr; 153(1):158-164. PubMed ID: 30630630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
    Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
    Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment with a PI3K/Akt/mTOR pathway inhibitor overcomes resistance to anti-HER2 therapy in PIK3CA-mutant HER2-positive breast cancer cells.
    Fujimoto Y; Morita TY; Ohashi A; Haeno H; Hakozaki Y; Fujii M; Kashima Y; Kobayashi SS; Mukohara T
    Sci Rep; 2020 Dec; 10(1):21762. PubMed ID: 33303839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The H1047R PIK3CA oncogene induces a senescence-like state, pleiotropy and acute HSP90 dependency in HER2+ mammary epithelial cells.
    Chakrabarty A; Surendran S; Bhola NE; Mishra VS; Wani TH; Baghel KS; Arteaga CL; Garg R; Chowdhury G
    Carcinogenesis; 2019 Oct; 40(10):1179-1190. PubMed ID: 31219154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines.
    Kataoka Y; Mukohara T; Shimada H; Saijo N; Hirai M; Minami H
    Ann Oncol; 2010 Feb; 21(2):255-262. PubMed ID: 19633047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies.
    Hanker AB; Pfefferle AD; Balko JM; Kuba MG; Young CD; Sánchez V; Sutton CR; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
    Proc Natl Acad Sci U S A; 2013 Aug; 110(35):14372-7. PubMed ID: 23940356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.
    Ebi H; Costa C; Faber AC; Nishtala M; Kotani H; Juric D; Della Pelle P; Song Y; Yano S; Mino-Kenudson M; Benes CH; Engelman JA
    Proc Natl Acad Sci U S A; 2013 Dec; 110(52):21124-9. PubMed ID: 24327733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of BIM induction and survivin downregulation in lapatinib-induced apoptosis in breast cancer cells with HER2 amplification.
    Tanizaki J; Okamoto I; Fumita S; Okamoto W; Nishio K; Nakagawa K
    Oncogene; 2011 Sep; 30(39):4097-106. PubMed ID: 21499301
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC; Du J; Lahdenranta J; Onsum MD; Nielsen UB; Schoeberl B; McDonagh CF
    PLoS Comput Biol; 2016 Apr; 12(4):e1004827. PubMed ID: 27035903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Membrane metallo-endopeptidase mediates cellular senescence induced by oncogenic PIK3CA
    Liu XL; Liu JL; Xu YC; Zhang X; Wang YX; Qing LH; Guo W; Ding J; Meng LH
    Int J Cancer; 2019 Aug; 145(3):817-829. PubMed ID: 30671946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer.
    Sukawa Y; Yamamoto H; Nosho K; Kunimoto H; Suzuki H; Adachi Y; Nakazawa M; Nobuoka T; Kawayama M; Mikami M; Matsuno T; Hasegawa T; Hirata K; Imai K; Shinomura Y
    World J Gastroenterol; 2012 Dec; 18(45):6577-86. PubMed ID: 23236232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers.
    Castaneda CA; Lopez-Ilasaca M; Pinto JA; Chirinos-Arias M; Doimi F; Neciosup SP; Rojas KI; Vidaurre T; Balko JM; Arteaga CL; Gomez HL
    Hematol Oncol Stem Cell Ther; 2014 Dec; 7(4):142-8. PubMed ID: 25467032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin.
    Cufí S; Corominas-Faja B; Lopez-Bonet E; Bonavia R; Pernas S; López IÁ; Dorca J; Martínez S; López NB; Fernández SD; Cuyàs E; Visa J; Rodríguez-Gallego E; Quirantes-Piné R; Segura-Carretero A; Joven J; Martin-Castillo B; Menendez JA
    Oncotarget; 2013 Sep; 4(9):1484-95. PubMed ID: 23986086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative oncogenic effect and cell signaling crosstalk of co‑occurring HER2 and mutant PIK3CA in mammary epithelial cells.
    Dong L; Meng F; Wu L; Mitchell AV; Block CJ; Zhang B; Craig DB; Jang H; Chen W; Yang Q; Wu G
    Int J Oncol; 2017 Oct; 51(4):1320-1330. PubMed ID: 28902361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initiating breast cancer by PIK3CA mutation.
    Miller TW
    Breast Cancer Res; 2012 Feb; 14(1):301. PubMed ID: 22315990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.